Taro Pharmaceutical Indus... (TARO)
NYSE: TARO
· Real-Time Price · USD
42.98
0.01 (0.02%)
At close: Jun 21, 2024, 9:59 PM
Taro Pharmaceutical Industries Income Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
Revenue | 164.94M | 157.15M | 148.2M | 158.89M | 146.59M | 139.2M | 130.5M | 156.66M | 143.26M | 138.98M | 131.99M | 147.11M | 148.35M | 140.15M | 142.84M | 117.63M |
Cost of Revenue | 77.55M | 77.26M | 74.6M | 94.81M | 70.88M | 75.16M | 83.54M | 75.06M | 65.92M | 62.95M | 69.94M | 69.42M | 71.41M | 66.96M | 61.26M | 52.69M |
Gross Profit | 87.39M | 79.88M | 73.6M | 64.08M | 75.71M | 64.05M | 46.96M | 81.61M | 77.34M | 76.03M | 62.05M | 77.7M | 76.93M | 73.19M | 81.59M | 64.95M |
Operating Income | 8.78M | 15.88M | 4.74M | -7.92M | 9.27M | 1.28M | -4.03M | 13.98M | 12.07M | 36.97M | 24.45M | -19.23M | -41.89M | 36.31M | 40.96M | -449.16M |
Interest Income | 15.83M | 15.5M | 13.97M | 10.89M | 8.04M | 6.59M | 4.3M | 1.93M | 685K | 2.09M | 2.37M | 3.04M | 3.19M | 4M | 5.68M | 7.31M |
Pretax Income | 26.23M | 33.34M | 17.66M | 5.44M | 17.9M | 9.17M | -4.91M | 16.05M | 25.02M | 39.5M | 29.42M | -16.08M | -37.76M | 39.14M | 48.65M | -441.1M |
Net Income | 15.08M | 20.21M | 8.55M | 10.03M | 6.91M | 7.26M | -2.81M | 14.08M | 27.4M | 26.31M | 23.32M | -18.77M | -29.79M | 32.92M | 45.13M | -434.92M |
Selling & General & Admin | 58.13M | 50.41M | 54.54M | 55.86M | 50.13M | 49.86M | 42.26M | 56.12M | 41.17M | 24.84M | 23.68M | 23.98M | 22.23M | 22.8M | 24.07M | 22.25M |
Research & Development | 20.48M | 13.59M | 14.32M | 16.14M | 16.31M | 12.91M | 11.52M | 11.51M | 14.89M | 14.2M | 12.49M | 12.95M | 16.59M | 14.08M | 16.55M | 12.93M |
Other Expenses | n/a | n/a | 566K | 390K | n/a | 563K | 395K | 445K | 512K | n/a | n/a | n/a | 100K | n/a | n/a | n/a |
Operating Expenses | 78.61M | 64M | 68.86M | 72.01M | 66.43M | 62.77M | 53.78M | 67.63M | 56.07M | 39.04M | 36.18M | 36.93M | 38.82M | 36.88M | 40.63M | 35.18M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 6.76M | 4.3M | 1.93M | 686K | 2.09M | 2.37M | 3.04M | 3.19M | 4M | 5.68M | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 14.51M | n/a | n/a | n/a | 8.28M | n/a | n/a | n/a | 5.68M | n/a | n/a | n/a |
Cost & Expenses | 156.16M | 141.26M | 143.46M | 166.82M | 137.31M | 137.92M | 137.31M | 142.69M | 121.99M | 101.99M | 106.12M | 106.34M | 110.23M | 103.84M | 101.88M | 87.87M |
Income Tax Expense | 11.15M | 13.14M | 9.11M | -4.59M | 10.99M | 1.91M | -2.1M | 1.97M | -2.39M | 13.19M | 6.1M | 2.69M | -8.88M | 6.1M | 3.59M | 8.85M |
Shares Outstanding (Basic) | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.6M | 37.53M | 38.07M | 38.25M | 38.26M | 38.25M |
Shares Outstanding (Diluted) | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.58M | 37.6M | 37.79M | 38.07M | 38.25M | 38.26M | 38.26M |
EPS (Basic) | 0.40 | 0.54 | 0.23 | 0.27 | 0.18 | 0.19 | -0.07 | 0.37 | 0.73 | 0.70 | 0.62 | -0.5 | -0.78 | 0.86 | 1.18 | -11.37 |
EPS (Diluted) | 0.40 | 0.54 | 0.23 | 0.27 | 0.18 | 0.19 | -0.07 | 0.37 | 0.73 | 0.70 | 0.62 | -0.5 | -0.78 | 0.86 | 1.18 | -11.37 |
EBITDA | 18.06M | 23.12M | 13.97M | 6.17M | 20.08M | 7.87M | 2.99M | 21.25M | 27.95M | 44.02M | 33.47M | 40.77M | -41.89M | 44.32M | 46.12M | -449.16M |
EBIT | 9.84M | 15.74M | 6.36M | -1.72M | 19.61M | 15.93M | -617K | 17.98M | 25.7M | 41.59M | 31.79M | -13.04M | -34.58M | 43.14M | 54.33M | -448.41M |
Depreciation & Amortization | 8.22M | 7.37M | 7.61M | 7.89M | 469K | -7.33M | 7.02M | 7.27M | 6.67M | 6.45M | 6.45M | 6.35M | 6.34M | 5.98M | 5.79M | 5.57M |